Why the study?
Do selective COX-2 inhibitors increase the risk of cardiovascular thrombotic events compared to traditional NSAIDs in patients with arthritis?
Do selective COX-2 inhibitors increase the risk of cardiovascular thrombotic events compared to traditional NSAIDs in patients with arthritis?
No takes yet. Share an insight, caveat, or question.
This editorial highlights potential cardiovascular safety concerns associated with selective COX-2 inhibitors compared to traditional NSAIDs, prompting further scrutiny of their thrombotic risk.
Strand et al. (2002) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: